Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia

详细信息    查看全文

• 作者：Kaiwei Liang¹ ; ² ; Andrew G. Volk¹ ; ³ ; Jeffrey S. Haug² ; Stacy A. Marshall¹ ; Ashley R. Woodfin¹ ; Elizabeth T. Bartom¹ ; Joshua M. Gilmore² ; Laurence Florens² ; Michael P. Washburn² ; ⁴ ; Kelly D. Sullivan⁵ ; Joaquin M. Espinosa⁵ ; Joseph Cannova⁶ ; ⁷ ; Jiwang Zhang⁶ ; ⁷ ; Edwin R. Smith¹ ; John D. Crispino¹ ; ³ ; ⁸ ; Ali Shilatifard¹ ; ² ; ⁸ ; ⁹ ; ^{ash@northwestern.edu}
• 关键词：mixed-lineage leukemia ; MLL ; wild-type MLL ; MLL chimera ; UBE2O ; interleukin-1 ; IRAK4 ; IRAK1 ; super elongation complex ; SEC
• 刊名：Cell
• 出版年：2017
• 出版时间：12 January 2017
• 年：2017
• 卷：168
• 期：1-2
• 页码：59-72.e13
• 全文大小：8259 K
• 卷排序：168

文摘

UBE2O acts downstream of the interleukin-1 pathway to regulate MLL/COMPASS stability Stabilizing wild-type MLL protein inhibits MLL leukemia cell proliferation UBE2O and IRAK inhibition alters a common set of MLL chimera target genes Targeting the IL-1 pathway is a potential therapeutic strategy for MLL leukemia